Le certolizumab pegol dans le traitement de la spondyloarthrite axiale : résultats à 4 ans de l’étude RAPID-axSpA

Translated title of the contribution: Certolizumab pegol for the treatment of axial spondyloarthritis: 4-year outcomes from the RAPID-axSpA trial

M. Breban, D. Van Der Heijde, M. Dougados, R. Landewé, J. Sieper, W. Maksymowych, M. Rudwaleit, F. Van den bosch, J. Braun, P. J. Mease, O. Davies, B. HŒpken, L. Peterson, A. Deodhar

Research output: Contribution to journalArticlepeer-review

Translated title of the contributionCertolizumab pegol for the treatment of axial spondyloarthritis: 4-year outcomes from the RAPID-axSpA trial
Original languageFrench
Pages (from-to)A226-A227
JournalRevue du Rhumatisme (Edition Francaise)
Volume83
DOIs
StatePublished - Nov 1 2016

ASJC Scopus subject areas

  • Rheumatology

Cite this